Ultragenyx Announces Upcoming Investor Conferences
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a company dedicated to developing innovative treatments for serious rare and ultra-rare genetic diseases, has declared its participation in several prominent investor conferences this September. These gatherings provide an excellent opportunity for the firm to exhibit its advancements in the biopharmaceutical field.
Cantor Global Healthcare Conference
Event Details
The first major event is the Cantor Global Healthcare Conference occurring early in September. On Thursday, September 4, the Chief Medical Officer, Dr. Eric Crombez, and Chief Financial Officer, Howard Horn, will engage in a fireside chat. They will also conduct one-on-one meetings with investors to discuss Ultragenyx's ongoing projects and future outlook.
Morgan Stanley Annual Global Healthcare Conference
Event Insights
Following the Cantor conference, Ultragenyx will also be participating in the highly anticipated Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9. During this gathering, Dr. Crombez will again take the stage for a fireside chat and will meet individually with investors to address their inquiries regarding the company’s strategies and innovations.
Bank of America Global Healthcare Conference
Participation Overview
Lastly, Ultragenyx will showcase its vision at the Bank of America Global Healthcare Conference, taking place on September 23. Dr. Crombez is slated to present a fireside chat once more and will host one-on-one discussions on the company's research and development initiatives, focusing on therapies for rare diseases.
Webcast Access and Future Engagements
For those wishing to catch the presentations, the live and archived webcasts will be available on Ultragenyx’s official website. This will allow interested parties to stay informed about the company’s latest advancements in the biopharmaceutical industry.
Company Overview
Ultragenyx is committed to finding unique solutions for patients suffering from rare genetic conditions. Over the years, the company has built an expansive portfolio of approved therapies that target diseases often lacking adequate treatment options. This dedication reflects Ultragenyx’s mission to meet the needs of patients with unmet medical needs, and they continue to emphasize a rapid approach to drug development.
Management Team and Strategic Focus
With a leadership team boasting extensive experience in the rare disease sector, Ultragenyx employs a strategy focused on efficient drug development. Their goal is to develop safe and effective therapies for patients in urgent need. They ensure that their research efforts are straightforward, guided by clear scientific understanding, and paced to hasten the availability of solutions.
Connect with Ultragenyx
If you're interested in learning more about Ultragenyx, additional details can be found on their official website. They also encourage queries directed to their Investor Relations team for pressing investor-related questions.
Contacts – Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Frequently Asked Questions
What is the purpose of the conferences Ultragenyx is attending?
These conferences provide Ultragenyx an opportunity to showcase their advancements in therapies for rare genetic diseases and engage with investors.
Who will represent Ultragenyx at these conferences?
The presentations will be led by Dr. Eric Crombez, Chief Medical Officer, and Howard Horn, Chief Financial Officer.
How can investors access the conference presentations?
Investors can access the live and archived webcasts through Ultragenyx’s official website.
What is Ultragenyx’s main focus?
Ultragenyx focuses on developing innovative treatments for serious rare and ultra-rare genetic disorders.
How does Ultragenyx approach drug development?
Ultragenyx employs a strategy prioritizing time and cost efficiency to expedite the delivery of safe therapies to patients in need.
